Dr. Achim Schneeberger has over 20 years’ experience in biomedical research and development focusing on immunotherapeutic approaches in cancer and chronic diseases. Following the study of Medicine at the Universities of Tübingen, Germany and Bordeaux, France, he started his career at the Department of Dermatology, Medical University of Vienna, Austria. At the time, he studied melanoma vaccines and was instrumental in translating the most promising candidates into the arena of clinical testing. This work and its results led to several prizes including the thesis award of the Medical University of Tübingen and the Egner Dermatooncology Prize of the German Dermatological Research Society. In 2005, Dr. Schneeberger joined the Laboratory of Prof. Yokoyama at Washington University, Saint Louis, to study the interactions between NK cells and cancer. Upon returning to Europe, he joined AFFiRiS to build and lead their clinical department. As CMO, he was responsible for the clinical development of the company’s vaccine candidates. Under his lead, AFFiRiS initiated clinical programs in the indications of Alzheimer’s, Parkinson’s, MSA and atherosclerosis covering a total of 18 clinical trials. He was instrumental for AFFiRiS being awarded with significant grants from the Michael J. Fox Foundation and the European Union (FP7 programs SYMPATH and MultiSYN).